Skip to main content

Table 1 Baseline Patient and Tumour Characteristics

From: Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictive and prognostic markers in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiation

Variable   Total (n = 1237) NLR p-val PLR p-val
<  4 (n = 912, 74%) ≥ 4 (n = 325, 26%) <  150 (n = 418, 34%) ≥ 150 (n = 819, 66%)
Province, n (%) Alberta 595 (48) 435 (48) 160 (49) NS 226 (54) 369 (45) < 0.01
British Columbia 255 (21) 186 (20) 69 (21)   69 (17) 186 (23)  
Ontario 387 (31) 291 (32) 96 (30)   123 (29) 264 (32)  
Age, years Median (range) 62 (23–88) 61 (23–88) 64 (24–87) < 0.01 62 (23–85) 62 (23–88) NS
≥65, n (%) 482 (39) 334 (37) 148 (46) < 0.01 154 (37) 328 (40) NS
Male, n (%)   858 (69) 632 (69) 226 (70) NS 302 (72) 556 (68) NS
BMI, kg/m2 | n = 1130 ≥ 25, n (%) 729 (59) 553 (61) 176 (54) NS 272 (65) 457 (56) < 0.01
ECOG PS, n (%) 0 524 (42) 398 (44) 126 (39) < 0.01 188 (45) 336 (41) NS
1 466 (38) 344 (38) 122 (38)   160 (38) 306 (37)  
2+ 62 (5) 32 (4) 30 (9)   13 (3) 49 (6)  
Unknown 185 (15) 138 (15) 47 (14)   57 (14) 128 (16)  
Distance from anal verge, n (%) | n = 1166 Median (range) 6 (0–30) 6 (0–30) 6 (0–25) NS 6 (0–20) 6 (0–30) NS
<  5 cm 415 (34) 306 (33) 109 (34) NS 137 (33) 278 (34) NS
5–10 cm 507 (41) 381 (42) 126 (39)   178 (43) 329 (40)  
>  10 cm 244 (20) 181 (20) 63 (19)   84 (20) 160 (20)  
Unknown 71 (6) 44 (5) 27 (8)   19 (4) 52 (6)  
Pre-treatment CEA, n (%) | n = 1093 Median (range) 4 (0–1133) 3 (0–857) 4 (0–1133) NS 3 (0–468) 4 (0–1133) NS
<  5 ng/mL 667 (54) 510 (56) 157 (48) NS 230 (55) 437 (53) NS
≥ 5 ng/mL 426 (34) 301 (33) 125 (39)   142 (34) 284 (35)  
Unknown 144 (12) 101 (11) 43 (13)   46 (11) 98 (12)  
Clinical stage, n (%) II 341 (28) 253 (28) 88 (27) NS 119 (28) 222 (27) NS
III 880 (71) 644 (71) 236 (73)   291 (70) 589 (72)  
Unknown 16 (1) 15 (2) 1 (0)   8 (2) 8 (1)  
Hemoglobin (g/dl) Median (range) 136 (68–183) 137 (68–183) 131 (68–178) < 0.01 140 (93–183) 133 (68–178) < 0.01
  1. BMI Body Mass Index, ECOG PS Eastern Cooperative Oncology Group Performance Status, CEA Carcinoembryonic Antigen, NLR Neutrophil-to-lymphocyte ratio, NS Non-significant, PLR Platelet-to-lymphocyte ratio